- Home
- COYA vs CRBU Comparison
COYA vs CRBU Comparison
Compare COYA & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | CRBU |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 145.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | COYA | CRBU |
|---|---|---|
| Price | $4.71 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $15.80 | $10.75 |
| AVG Volume (30 Days) | 166.6K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $763.10 | $10.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $1.38 |
| 52 Week High | $7.75 | $3.53 |
Technical Indicators
Market Signals| Indicator | COYA | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.